PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · World J Nucl Med 2021; 20(01): 7-16
DOI: 10.4103/wjnm.WJNM_85_20
Review Article

18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging review of benign lesions of the thorax

Autor*innen

  • Reddy Ravikanth

    Department of Radiology, St. John's Hospital, Kattappana, Kerala, India
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

2-deoxy-2-(Fluorine-18) fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has been used exclusively to diagnose malignancies. However, increased 18F-FDG uptake is not always limited to malignant lesions. This imaging review demonstrates the physiological 18F-FDG uptake of normal structures in the thorax and illustrates many benign pathological lesions with standardized uptake value >2.5. These various conditions can be broadly categorized into three groups: infective lesions, active granulomatous diseases such as sarcoidosis, noninfectious/inflammatory, or proliferative conditions such as radiation pneumonitis, postlung transplant lymphoproliferative disorders, occupational pleuropulmonary complications, and postsurgical conditions, all of which can demonstrate varying degrees of 18F-FDG uptake on PET/CT based upon the degree of inflammatory activity. Familiarity of false-positive findings improves the PET/CT evaluation accuracy of benign lesions of the thorax. Radiation exposure and surgical history correlation along with imaging cross check evaluation of radiographs and magnetic resonance images for the anatomic location remains the mainstay of PET/CT characterization of positive findings.

Keywords

2-deoxy-2-(Fluorine-18) fluoro-D-glucose positron emission tomography/computed tomography - active granulomatous diseases - benign lesions of the thorax - infective lesions - inflammatory or proliferative conditions

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 20. Juni 2020

Angenommen: 29. Juni 2020

Artikel online veröffentlicht:
30. März 2022

© 2021. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Truong MT, Pan T, Erasmus JJ. Pitfalls in integrated CT-PET of the thorax: Implications in oncologic imaging. J Thorac Imaging 2006;21:111-22.
  • 2 Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol 2006;7:57-69.
  • 3 Jackson RS, Schlarman TC, Hubble WL, Osman MM. Prevalence and patterns of physiologic muscle uptake detected with whole-body 18F-FDG PET. J Nucl Med Technol 2006;34:29-33.
  • 4 Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake-the role of PET/CT. Eur Radiol 2006;16:1054-65.
  • 5 Kavanagh PV, Stevenson AW, Chen MY, Clark PB. Nonneoplastic diseases in the chest showing increased activity on FDG PET. AJR Am J Roentgenol 2004;183:1133-41.
  • 6 Cronin CG, Prakash P, Daniels GH, Boland GW, Kalra MK, Halpern EF, et al. Brown fat at PET/CT: Correlation with patient characteristics. Radiology 2012;263:836-42.
  • 7 Maurer AH, Burshteyn M, Adler LP, Steiner RM. How to differentiate benign versus malignant cardiac and paracardiac 18F FDG uptake at oncologic PET/CT. Radiographics 2011;31:1287-305.
  • 8 Franceschi AM, Matthews R, Mankes S, Safaie E, Franceschi D. Four chamber FDG uptake in the heart: An indirect sign of pulmonary embolism. Clin Nucl Med 2012;37:687-91.
  • 9 Lobert P, Brown RK, Dvorak RA, Corbett JR, Kazerooni EA, Wong KK. Spectrum of physiological and pathological cardiac and pericardial uptake of FDG in oncology PET-CT. Clin Radiol 2013;68:e59-71.
  • 10 Kuester LB, Fischman AJ, Fan CM, Halpern EF, Aquino SL. Lipomatous hypertrophy of the interatrial septum: Prevalence and features on fusion 18F fluorodeoxyglucose positron emission tomography/CT. Chest 2005;128:3888-93.
  • 11 Fukuchi K, Ohta H, Matsumura K, Ishida Y. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies. Br J Radiol 2007;80:3-11.
  • 12 Kim JH, Cho JH, Park MS, Chung JH, Lee JG, Kim YS, et al. Pulmonary inflammatory pseudotumor-a report of 28 cases. Korean J Intern Med 2002;17:252-8.
  • 13 Alongi F, Bolognesi A, Samanes Gajate AM, Motta M, Landoni C, Berardi G, et al. Inflammatory pseudotumor of mediastinum treated with tomotherapy and monitored with FDG-PET/CT: Case report and literature review. Tumori 2010;96:322-6.
  • 14 Kitada M, Matuda Y, Hayashi S, Ishibashi K, Oikawa K, Miyokawa N, et al. IgG4-related lung disease showing high standardized uptake values on FDG-PET: Report of two cases. J Cardiothorac Surg 2013;8:160.
  • 15 Gotway MB, Storto ML, Golden JA, Reddy GP, Webb WR. Incidental detection of thoracic sarcoidosis on whole-body 18fluorine-2- fluoro-2-deoxy-D-glucose positron emission tomography. J Thorac Imaging 2000;15:201-4.
  • 16 Basu S, Saboury B, Werner T, Alavi A. Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders. Mol Imaging Biol 2011;13:1051-60.
  • 17 Reichert M, Bensadoun ES. PET imaging in patients with coal workers pneumoconiosis and suspected malignancy. J Thorac Oncol 2009;4:649-51.
  • 18 Saydam O, Gokce M, Kilicgun A, Tanriverdi O. Accuracy of positron emission tomography in mediastinal node assessment in coal workers with lung cancer. Med Oncol 2012;29:589-94.
  • 19 Nakadate M, Yoshida K, Ishii A, Koizumi M, Tochigi N, Suzuki Y, et al. Is 18F-FDG PET/CT useful for distinguishing between primary thyroid lymphoma and chronic thyroiditis? Clin Nucl Med 2013;38:709-14.
  • 20 Bakheet SM, Saleem M, Powe J, Al-Amro A, Larsson SG, Mahassin Z. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 2000;25:273-8.
  • 21 Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, et al. Pulmonary tuberculoma evaluated by means of FDG PET: Findings in 10 cases. Radiology 2000;216:117-21.
  • 22 Kapucu LO, Meltzer CC, Townsend DW, Keenan RJ, Luketich JD. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med 1998;39:1267-9.
  • 23 Aznar MC, Korreman SS, Pedersen AN, Persson GF, Josipovic M, Specht L. Evaluation of dose to cardiac structures during breast irradiation. Br J Radiol 2011;84:743-6.
  • 24 Prosnitz RG, Hubbs JL, Evans ES, Zhou SM, Yu X, Blazing MA, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: Analysis of data 3 to 6 years after treatment. Cancer 2007;110:1840-50.
  • 25 Asad S, Aquino SL, Piyavisetpat N, Fischman AJ. False-positive FDG positron emission tomography uptake in nonmalignant chest abnormalities. AJR Am J Roentgenol 2004;182:983-9.
  • 26 Schreiter N, Nogami M, Buchert R, Froeling V, Brenner W, Diekmann F. Pulmonary FDG uptake without a CT counterpart-a pitfall in interpreting PET/CT images. Acta Radiol 2011;52:513-5.
  • 27 Culverwell AD, Scarsbrook AF, Chowdhury FU. False-positive uptake on 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging. Clin Radiol 2011;66:366-82.
  • 28 Bredella MA, Essary B, Torriani M, Ouellette HA, Palmer WE. Use of FDG-PET in differentiating benign from malignant compression fractures. Skeletal Radiol 2008;37:405-13.
  • 29 Beaulieu S, Rubin B, Djang D, Conrad E, Turcotte E, Eary JF. Positron emission tomography of schwannomas: Emphasizing its potential in preoperative planning. AJR Am J Roentgenol 2004;182:971-4.
  • 30 Hamada K, Ueda T, Higuchi I, Inoue A, Tamai N, Myoi A, et al. Peripheral nerve schwannoma: Two cases exhibiting increased FDG uptake in early and delayed PET imaging. Skeletal Radiol 2005;34:52-7.
  • 31 Basu S, Nair N, Banavali S. Uptake characteristics of fluorodeoxyglucose (FDG) in deep fibromatosis and abdominal desmoids: Potential clinical role of FDG-PET in the management. Br J Radiol 2007;80:750-6.
  • 32 Ochsner JE, Sewall SA, Brooks GN, Agni R. Best cases from the AFIP: Elastofibroma dorsi. Radiographics 2006;26:1873-6.
  • 33 Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors: Standardized uptake value in 52 lesions. Radiology 2001;219:774-7.
  • 34 Costelloe CM, Murphy WA Jr, Chasen BA. Musculoskeletal pitfalls in 18F-FDG PET/CT: Pictorial review. AJR Am J Roentgenol 2009;193:WS1-13, Quiz S26-30.
  • 35 Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002;32:293-321.